Patricia Dauer
University of Chicago
H-index: 14
North America-United States
Top articles of Patricia Dauer
Abstract PO1-28-01: MammaPrint and BluePrint identify racial disparities among women with HR+ HER2-early-stage breast cancer
Cancer Research
2024/5/2
Xiao-Ou Shu
H-Index: 85
Patricia Dauer
H-Index: 13
OPEN ACCESS EDITED BY
Community Series-Extremophiles: Microbial Genomics and Taxogenomics, Volume II
2023/11/22
ASO Visual Abstract: The Predictive Utility of MammaPrint and BluePrint in Identifying Patients with Locally Advanced Breast Cancer Who are Most Likely to have Nodal …
Annals of surgical oncology
2024/1
Mehran Habibi
H-Index: 8
Patricia Dauer
H-Index: 13
The Predictive Utility of MammaPrint and BluePrint in Identifying Patients with Locally Advanced Breast Cancer Who are Most Likely to Have Nodal Downstaging and a Pathologic …
Annals of surgical oncology
2023/12
Mehran Habibi
H-Index: 8
Patricia Dauer
H-Index: 13
Bioflavonoid luteolin prevents sFlt‐1 release via HIF‐1α inhibition in cultured human placenta
The FASEB Journal
2023/8
Impact of race on BluePrint genomic subtyping in HER2+ breast cancer.
2023/6/1
Xiao-Ou Shu
H-Index: 85
Patricia Dauer
H-Index: 13
Preeclampsia pathophysiology and adverse outcomes during pregnancy and postpartum
2023/3/16
Abstract PD9-08: ImPrint immune signature in 10,000 early-stage breast cancer patients from the real-world FLEX database
Cancer Research
2023/3/1
Ajay Dhakal
H-Index: 3
Patricia Dauer
H-Index: 13
Abstract P5-09-02: Impact of neoadjuvant endocrine therapy on tumor transcriptome in patients with early-stage breast cancer from the FLEX trial
Cancer Research
2023/3/1
Mehran Habibi
H-Index: 8
Patricia Dauer
H-Index: 13
Combined 70-and 80-gene signatures identify tumors with genomically luminal biology responsive to neoadjuvant endocrine therapy and are prognostic of 5-year outcome in early …
Surgical Oncology
2022/12/1
Shiyu Wang
H-Index: 8
Patricia Dauer
H-Index: 13
Genomic classification of HER2-positive patients with 80-gene and 70-gene signatures identifies diversity in clinical outcomes With HER2-targeted neoadjuvant therapy
JCO Precision Oncology
2022/9
Shiyu Wang
H-Index: 8
Patricia Dauer
H-Index: 13
Identification of transcriptional changes with MammaPrint and BluePrint in early-stage breast cancer after neoadjuvant chemotherapy.
2022/6/1
Whole transcriptomic analysis of HR+ breast cancer in Black women classified as basal-type by BluePrint.
2022/6/1
High concordance of 70‐gene recurrence risk signature and 80‐gene molecular subtyping signature between core needle biopsy and surgical resection specimens in early‐stage …
Journal of Surgical Oncology
2022/3
Patricia Dauer
H-Index: 13
Shiyu Wang
H-Index: 8
Deciphering the inferior prognosis of young women with estrogen receptor-positive early-stage breast cancer through full transcriptome analysis: A FLEX database sub-study
2022/2/15
Shiyu Wang
H-Index: 8
Patricia Dauer
H-Index: 13
Abstract P5-07-05: Deciphering the inferior prognosis of young women with estrogen receptor-positive early-stage breast cancer through full transcriptome analysis: A FLEX …
Cancer Research
2022/2/15
Shiyu Wang
H-Index: 8
Patricia Dauer
H-Index: 13
Defining transcriptomic profiles of breast cancer with early lymph node metastases: A FLEX database sub-study
2022/2/15
Shiyu Wang
H-Index: 8
Patricia Dauer
H-Index: 13
